HMOX1 and Hepatic steatosis: Treatment of mice with obesity-induced NAFLD with bilirubin nanoparticles reduced hepatic steatosis and improved liver function, lowering AST liver dysfunction marker [35], suggesting that HO-1 protection against NALFD may be mediated by bilirubin.